Results 261 to 270 of about 99,296 (339)

Advances in the treatment of hepatocellular carcinoma: An overview of the current and evolving therapeutic landscape for clinicians

CA: A Cancer Journal for Clinicians, EarlyView.
Abstract Hepatocellular carcinoma (HCC) is the sixth most common malignancy and the third leading cause of cancer‐related death worldwide. Contemporary advances in systemic and locoregional therapies have led to changes in peer‐reviewed guidelines regarding systemic therapy as well as the possibility of downstaging disease that may enable some patients
Dimitrios Moris, Alessandro Martinino, Sarah Schiltz, Peter J. Allen, Andrew Barbas, Debra Sudan, Lindsay King, Carl Berg, Charles Kim, Mustafa Bashir, Manisha Palta, Michael A. Morse, Michael E. Lidsky   +12 more
wiley   +1 more source

The impact of interstitial lung disease in patients with acid sphingomyelinase deficiency (ASMD) - A case series. [PDF]

Respir Med Case Rep
Costa I Colomer J, Garcia-Moyano M, Maiz L, Perez-Tarazona S, Ruiz de Valbuena M, Ceberio L, Correcher P, Juliá-Palacios N, Morales M, Pérez-Yagüe G, Villarrubia J, Pérez-Rojo R.   +11 more
europepmc   +1 more source

STUDIES ON THE ULTRA-STRUCTURE OF THE LIVER IN THE PATIENTS WITH SPLENOMEGALY

, 1968
Katsuaki Mohri
openalex   +2 more sources

Topics of Interest in Women With Myeloproliferative Neoplasms

American Journal of Hematology, Volume 100, Issue S4, Page 74-87, June 2025.
Women with MPN: life‐cycle phases, specific risks, and influencing factors. ABSTRACT Overview Sex and gender have emerged as central modifiers of disease biology, phenotype, and clinical outcomes in myeloproliferative neoplasms (MPNs). This review will uniquely highlight issues affecting women with MPN and articulate their relevant determinants ...
Natasha Szuber, Paola Guglielmelli, Naseema Gangat   +2 more
wiley   +1 more source

Immunosuppression of spleen in mice treated with erythropoietin: transcriptomic and immunological analysis. [PDF]

Front Immunol
Lyu X, Shi J, Liu Q, Jiang M, Liu X, Li Y, Ding S, Dai X.   +7 more
europepmc   +1 more source

Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial [PDF]

, 2017
DiPersio, John F, et al,
core   +1 more source

Preliminary Report on the Error of Blood Volume Determination in Splenomegaly

, 1967
Somneuk Gierasate
openalex   +2 more sources

Elucidating the Molecular Landscape of Cystic Kidney Disease: Old Friends, New Friends and Some Surprises

American Journal of Medical Genetics Part A, Volume 197, Issue 6, June 2025.
ABSTRACT Cystic kidney diseases (CyKD) are a diverse group of disorders affecting more than 1 in 1000 individuals. Over 120 genes are implicated, primarily encoding components of the primary cilium, transcription factors, and morphogens. Prognosis varies greatly by molecular diagnosis. Causal variants are not identified in 10%–60% of individuals due to
Deborah Watson, Frank Mentch, Jonathan Billings, Kayleigh Ostberg, Michael E. March, Jennifer M. Kalish, Dong Li, India Cannon, Lisa M. Guay‐Woodford, Erum Hartung, Alanna Strong   +10 more
wiley   +1 more source

A case report of hemothorax due to intrathoracic variceal rupture linked to Budd-Chiari syndrome. [PDF]

BMC Pulm Med
Hu Y, Deng Z, Chen Y, Wu T.
europepmc   +1 more source

Clinical evaluation and outcome in heart failure patients receiving chemotherapy with different anti‐cancer agents

ESC Heart Failure, Volume 12, Issue 3, Page 1965-1976, June 2025.
Abstract Background The optimal strategy for modern chemotherapy should be based on a comprehensive approach for cancer patients with cardiovascular diseases. Therefore, cardio‐oncology has received increasing attention owing to the cardiotoxic effects of anti‐cancer therapies.
Tomiko Sunaga, Takahiro Okada, Yoshitaka Iso, Mio Ebato, Tsutomu Toshida, Shuichi Nawata, Hiroshi Suzuki, Mari Kogo   +7 more
wiley   +1 more source